文献速递肝病消化道肿瘤与早癌

肝硬化患者肝细胞癌的发病率与危险因素:多中心肝细胞癌早期检测策略(HEDS)研究

Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study.
PubMed 文献 · Gastroenterology · 2023-07-08

该多中心前瞻性研究纳入1723例接受标准监测的肝硬化患者,中位随访2.2年,肝细胞癌发病率为2.4/100人年,81%为极早期/早期巴塞罗那临床肝癌分期;多因素分析确认男性、肝硬化年限、肝癌家族史、年龄、肥胖等为肝细胞癌危险因素。

要点

  • 肝硬化患者肝细胞癌发病率为2.4/100人年,81%为极早期/早期巴塞罗那临床肝癌分期。
  • 男性、肝硬化年限、肝癌家族史、年龄、肥胖与肝细胞癌风险独立相关。
  • 天冬氨酸氨基转移酶、甲胎蛋白和白蛋白在多因素分析中未达统计学显著。

核心结论

  • 这是迄今最大的美国肝硬化患者前瞻性、地理多样性队列研究,验证了肝细胞癌的已知危险因素(性别、年龄、肥胖、肝硬化年限、肝癌家族史、基线甲胎蛋白、白蛋白和天冬氨酸氨基转移酶)。
  • 肝细胞癌发病率为2.4/100人年。

研究设计与样本

  • 美国国立卫生研究院多中心肝细胞癌早期检测策略研究,前瞻性纳入接受标准监测的肝硬化患者。
  • 2013年4月10日至2021年12月31日共纳入并确认符合条件的患者1723例;危险因素分析限于随访至少6个月的1325例患者,其中95例发生肝细胞癌。
  • 中位随访2.2年(范围0-8.7年)。

主要发现

  • 随访期间共发生109例肝细胞癌,发病率为2.4/100人年;其中88例(81%)为极早期/早期巴塞罗那临床肝癌分期(0、A期),20例(18%)为中期(B期),1例(1%)分期未知。
  • 危险因素分析人群多数为男性(53.2%)、肥胖或重度肥胖(中位体重指数30.2 kg/m2)、白人(86.3%);42.0%有丙型肝炎病毒感染史,20.7%有酒精性肝病,24.9%有非酒精性脂肪性肝病。
  • 单因素分析中14个肝细胞癌危险因素显著(P < .05)。
  • 多因素子集包含性别(P < .001;男性;比值比[OR] 2.47;95%置信区间[CI] 1.54-4.07)、肝硬化年限(P = .004;OR 1.06;95% CI 1.02-1.1)、肝癌家族史(P = .02;有;OR 2.69;95% CI 1.11-5.86)、年龄(每5岁;P = .02;OR 1.17;95% CI 1.03-1.33)、肥胖(P = .02;有;OR 1.7;95% CI 1.08-2.73)。
  • 多因素子集中天冬氨酸氨基转移酶(log(1+AST);P = .06;OR 1.54;95% CI 0.97-2.42)、甲胎蛋白(log(1+AFP);P = .07;OR 1.32;95% CI 0.97-1.77)和白蛋白(P = .10;OR 0.7;95% CI 0.46-1.07)未达统计学显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Worldwide, hepatocellular carcinoma (HCC) is a common malignancy. We aimed to prospectively determine the incidence and risk factors of HCC in a U.S. METHODS: The multicenter Hepatocellular Carcinoma Early Detection Strategy study of the National Institutes of Health prospectively enrolled patients with cirrhosis who underwent standard surveillance for HCC. Demographics, medical and family history, etiology of liver disease, and clinical features were evaluated for associations with HCC. RESULTS: Between April 10, 2013 and December 31, 2021, 1723 patients were enrolled and confirmed eligible. During median follow-up of 2.2 years (range, 0-8.7 years), there were 109 incident cases of HCC for an incidence rate of 2.4 per 100 person-years: 88 (81%) patients with very early/early Barcelona Clinic Liver Cancer stage (0, A), 20 (18%) intermediate stage (B), and 1 (1%) unknown stage. Risk factor analyses were restricted to 1325 patients, including 95 incident HCC, with at least 6 months of follow-up. The majority were men (53.2%), obese or severely obese (median body mass index, 30.2 kg/m2), and white (86.3%); 42.0% had history of hepatitis C virus infection, 20.7% had alcoholic liver disease, and 24.9% had nonalcoholic fatty liver disease. Fourteen risk factors for HCC were significant (P < .05) in univariate analyses, and a multivariate subset was selected using stepwise logistic regression. The multivariate subset contained gender (P < .001; male; odds ratio [OR], 2.47; 95% confidence interval [CI], 1.54-4.07), years with cirrhosis (P = .004; OR, 1.06; 95% CI, 1.02-1.1), family history of liver cancer (P = .02; yes; OR, 2.69; 95% CI, 1.11-5.86), age (per 5 years; P = .02; OR, 1.17; 95% CI, 1.03-1.33), obesity (P = .02; yes; OR, 1.7; 95% CI, 1.08-2.73), aspartate aminotransferase (log(1+AST); P = .06; OR, 1.54; 95% CI, 0.97-2.42), alpha-fetoprotein (log(1+AFP); P = .07; OR, 1.32; 95% CI, 0.97-1.77), and albumin (P = .10; OR, 0.7; 95% CI, 0.46-1.07). CONCLUSIONS: Thus far, this is the largest prospective and geographically diverse study of a U.S. cohort of patients with cirrhosis that validates known risk factors for HCC (gender, age, obesity, years with cirrhosis, family history of liver cancer, baseline AFP, albumin, and AST). The incidence of HCC was 2.4% per 100 person-years.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Reddy KR, McLerran D, Marsh T, et al. Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study. Gastroenterology. 2023. PMID: 37429366. doi:10.1053/j.gastro.2023.06.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。